TNT is a phase 3, parallel group, open-label randomized controlled trial. 376 participants were allocated (in a 1:1 ratio) to groups that received six cycles of carboplatin (AUC 6), day 1 of a 3-weekly cycle, or six cycles of docetaxel (100 mg/m2), day 1 of a 3-weekly cycle. Subjects were offered six cycles of the alternative (crossover) treatment upon progression or where allocated treatment was discontinued due to toxicity (pre-progression crossover).

Clinical data and sample collection.